Compulsive redosing
Compulsive redosing is defined as the experience of a powerful and difficult to resist urge to continuously redose a psychoactive substance in an effort to increase or maintain the subjective effects which it induces.[1][2][3][4]
This effect is considerably more likely to manifest itself when the user has a large supply of the given substance within their possession. It can be partially avoided by pre-weighing dosages, not keeping the remaining material within sight, exerting self-control, and giving the compound to a trusted individual to keep until they deem it safe to return.
Compulsive redosing is often accompanied by other coinciding effects such as cognitive euphoria, physical euphoria, or anxiety suppression alongside of other effects which inhibit the clarity of one's decision-making processes such as disinhibition, motivation enhancement, and ego inflation. It is most commonly induced under the influence of moderate dosages of a wide variety of compounds, such as opioids, stimulants,[2][4][5] GABAergics,[2] and entactogens.[3] However, it can also occur to a lesser extent under the influence of dissociatives and cannabinoids.[3]
Psychoactive substances
MDPV is extremely potent in this effect; it has been shown that some users end up redosing, even if the negative effects outweigh the positives.[6][7]
Substances which may cause this effect include:
- 2-Aminoindane
- 2-FA
- 2-FEA
- 2-FMA
- 2-Fluorodeschloroketamine
- 2M2B
- 3-Cl-PCP
- 3-FA
- 3-FEA
- 3-FMA
- 3-HO-PCE
- 3-HO-PCP
- 3-MMC
- 3-MeO-PCE
- 3-MeO-PCMo
- 3-MeO-PCP
- 4-AcO-DiPT
- 4-FA
- 4-FMA
- 4-MeO-PCP
- 4F-MPH
- 5-APB
- 5-MAPB
- 6-APB
- 6-APDB
- A-PHP
- A-PVP
- Acetylfentanyl
- Alcohol
- Alprazolam
- Amphetamine
- Baclofen
- Barbiturates
- Benzodiazepines
- Bromazolam
- Caffeine
- Carisoprodol
- Clonazepam
- Clonazolam
- Cocaine
- Codeine
- Cyclazodone
- Deschloroetizolam
- Deschloroketamine
- Desomorphine
- Desoxypipradrol
- Dextropropoxyphene
- Diazepam
- Dichloropane
- Diclazepam
Experience reports
Anecdotal reports which describe this effect within our experience index include:
- Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
- Experience:1.2 g gabapentin, alcohol, and half of 150 mg Effexor XR - Pretty lovely for socializing and giggles
- Experience:100/100/100mg, first time with it
- Experience:110mg Diphenidine (vaporized) + 354mg DXM - instant ego death
- Experience:1g Methiopropamine - Chasing the Chalky Dragon
- Experience:20mg Etizolam - Smoking Etizolam
- Experience:20mg Heroin - The Last Time I Shot Up
- Experience:25mg 3-MeO-PCP - Enhanced film experience
- Experience:25mg Deschloroketamine - My first time orally dosing DCK
- Experience:260 mg Ketamine (insufflated) - Lost in Paisley
- Experience:2mg Etizolam & N2O - "Hippy Crack" Indeed
- Experience:2mg Etizolam - Here be dragons
- Experience:3-MeO-PCP - Extreme psychosis
- Experience:3-MeO-PCP, LSD, Clonazolam, and Amphetamine - Excessive Amounts and Excessive Confusion
- Experience:30mg Isopropylphenidate - IPPH As A Study Aid
- Experience:37mg Isopropylphenidate - Getting Shit Done With Isopropylphenidate
- Experience:3mg Etizolam - A Comedown Drug
- Experience:60mg Zolpidem - A Delirious Adventure
- Experience:A night with Ethylphenidate
- Experience:Alprazolam (24 mg) - Into the Void
- Experience:Datura and nicotine smoked - 4 and ~15 hits; was actually quite pleasant
- Experience:FMA (37.5 mg, oral) - Never been this productive in my life
- Experience:Nitrous oxide (approx. 50 puffs) - ~50 puffs nitrous oxide
See also
- Responsible use
- Subjective effects index
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Deliriants - Subjective effects
- N-Acetylcysteine
External links
References
- ↑ Everitt, Barry J; Robbins, Trevor W (2005). "Neural systems of reinforcement for drug addiction: from actions to habits to compulsion". Nature Neuroscience. 8 (11): 1481–1489. doi:10.1038/nn1579. ISSN 1097-6256.
- ↑ 2.0 2.1 2.2 Volkow, N. D. (2000). "Addiction, a Disease of Compulsion and Drive: Involvement of the Orbitofrontal Cortex". Cerebral Cortex. 10 (3): 318–325. doi:10.1093/cercor/10.3.318. ISSN 1460-2199.
- ↑ 3.0 3.1 3.2 Hyman, Steven E.; Malenka, Robert C. (2001). "Addiction and the brain: The neurobiology of compulsion and its persistence". Nature Reviews Neuroscience. 2 (10): 695–703. doi:10.1038/35094560. ISSN 1471-003X.
- ↑ 4.0 4.1 Soussan, Christophe; Kjellgren, Anette (2015). ""Chasing the High" – Experiences of Ethylphenidate as Described on International Internet Forums". Substance Abuse: Research and Treatment. 9: SART.S22495. doi:10.4137/SART.S22495. ISSN 1178-2218.
- ↑ Olives, Travis; Orozco, Benjamin; Stellpflug, Samuel (2012). "Bath Salts: The Ivory Wave of Trouble". Western Journal of Emergency Medicine. 13 (1): 58–62. doi:10.5811/westjem.2011.6.6782. ISSN 1936-900X.
- ↑ Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, et al. (March 2014). "Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)". Addiction Biology. 19 (2): 165–74. doi:10.1111/j.1369-1600.2012.00474.x. PMC 3473160 . PMID 22784198.
- ↑ Coppola M, Mondola R (January 2012). "3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online". Toxicology Letters. 208 (1): 12–5. doi:10.1016/j.toxlet.2011.10.002. PMID 22008731.